share_log

Ascendiant Capital Initiates Coverage On Vivos Therapeutics With Buy Rating, Announces Price Target of $2.5

Ascendiant Capital Initiates Coverage On Vivos Therapeutics With Buy Rating, Announces Price Target of $2.5

Ascendiant Capital以買入評級啓動對Vivos Therapeutics的報道,宣佈目標股價爲2.5美元
Benzinga Real-time News ·  2023/01/17 05:38

Ascendiant Capital analyst Edward Woo initiates coverage on Vivos Therapeutics (NASDAQ:VVOS) with a Buy rating and announces Price Target of $2.5.

Ascendiant Capital分析師愛德華·胡以買入評級啓動了對Vivos Therapeutics(納斯達克股票代碼:VVOS)的報道,並宣佈目標股價爲2.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論